Incyte Co. (NASDAQ:INCY) Shares Purchased by Delphi Management Inc. MA

Delphi Management Inc. MA increased its position in shares of Incyte Co. (NASDAQ:INCY) by 631.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,783 shares of the biopharmaceutical company’s stock after acquiring an additional 7,583 shares during the period. Delphi Management Inc. MA’s holdings in Incyte were worth $607,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Quintet Private Bank Europe S.A. acquired a new position in shares of Incyte in the 4th quarter valued at $26,000. Global X Japan Co. Ltd. boosted its position in shares of Incyte by 144.7% in the 4th quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 230 shares during the period. Brooklyn Investment Group acquired a new position in shares of Incyte in the 3rd quarter valued at $30,000. R Squared Ltd acquired a new position in shares of Incyte in the 4th quarter valued at $30,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Incyte in the 3rd quarter valued at $33,000. 96.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

INCY has been the subject of a number of research reports. Royal Bank of Canada decreased their price objective on Incyte from $70.00 to $68.00 and set a “sector perform” rating for the company in a research report on Tuesday, February 11th. StockNews.com lowered Incyte from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 12th. Cantor Fitzgerald restated a “neutral” rating on shares of Incyte in a research report on Friday, January 10th. UBS Group initiated coverage on Incyte in a research report on Tuesday, December 17th. They set a “neutral” rating and a $77.00 price objective for the company. Finally, Wells Fargo & Company raised their price objective on Incyte from $68.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Thursday, December 19th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $75.25.

Insider Transactions at Incyte

In other news, EVP Steven H. Stein sold 12,352 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $72.69, for a total transaction of $897,866.88. Following the completion of the transaction, the executive vice president now directly owns 66,967 shares in the company, valued at $4,867,831.23. The trade was a 15.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sheila A. Denton sold 599 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $69.99, for a total value of $41,924.01. Following the transaction, the executive vice president now owns 25,848 shares of the company’s stock, valued at approximately $1,809,101.52. This trade represents a 2.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 27,020 shares of company stock worth $1,981,882 over the last three months. 17.60% of the stock is currently owned by insiders.

Incyte Stock Down 8.6 %

INCY opened at $62.01 on Tuesday. The business has a 50 day moving average price of $71.55 and a 200 day moving average price of $70.31. Incyte Co. has a twelve month low of $50.35 and a twelve month high of $83.95. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.94 and a current ratio of 1.97. The firm has a market cap of $12.00 billion, a P/E ratio of 229.68, a price-to-earnings-growth ratio of 0.41 and a beta of 0.76.

Incyte (NASDAQ:INCY) last issued its quarterly earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%. Research analysts forecast that Incyte Co. will post 4.86 EPS for the current year.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.